Source-grounded facts extracted from Mineralys Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Mineralys Therapeutics, Inc. entered into Senior Secured Term Loan Agreement with BioPharma Credit PLC valued at Up to $500,000,000 in term loans (effective 2026-06-02).
“On June 2, 2026 (the “Closing Date”), the Company entered into a senior secured term loan agreement (the “Loan Agreement”) with BioPharma Credit PLC, as collateral agent (the “Agent”), and each of BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, which are funds managed by Pharmakon Advisors, LP, as lenders.”
Earnings Releases
Mineralys Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $39.3 million for the quarter ended March 31, 2026.
“On May 6, 2026, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026 and provided a corporate update.”
Olivier Litzka resigned as Director at Mineralys Therapeutics, Inc..
“Olivier Litzka, Ph.D. informed the Board of his decision to resign from the Board, effective June 13, 2024.”
Alexander M. Gold was appointed as Class I director at Mineralys Therapeutics, Inc..
“the Board appointed Alexander M. Gold, M.D. as a member of the Board and the Nominating and Corporate Governance Committee of the Board.”
Earnings Releases
Mineralys Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $31.5 million.
“Net loss was $31.5 million for the quarter ended March 31, 2024, compared to $12.6 million for the quarter ended March 31, 2023.”
Alexander Asam departed as Director at Mineralys Therapeutics, Inc..
“On March 29, 2024, Alexander Asam, Ph.D. informed the Board of Directors (the “Board”) of Mineralys Therapeutics, Inc. (the “Company”) of his decision not to stand for re-election to the Board when his current term expires at the Company’s 2024 annual meeting of stockholders.”
Earnings Releases
Mineralys Therapeutics, Inc. reported quarter and fiscal year ended December 31, 2023 results: net income Net loss was $71.9 million for the year ended December 31, 2023, compared to $29.8 million for the year ended December 3.
“Net loss was $71.9 million for the year ended December 31, 2023, compared to $29.8 million for the year ended December 31, 2022.”
Material Agreements
Mineralys Therapeutics, Inc. entered into ATM Equity Offering Sales Agreement with BofA Securities, Inc. and Evercore Group L.L.C. valued at $100,000,000 (effective 2024-03-21).
“On March 21, 2024, Mineralys Therapeutics, Inc. (the “Company”), entered into an ATM Equity Offering Sales Agreement (the “Agreement”) with BofA Securities, Inc. and Evercore Group L.L.C. as the Company’s sales agents (the “Agents”) and/or principals. Pursuant to the terms of the Agreement, the Company may sell from time to time through the Agents shares of the Company’s common stock having an aggregate offering price of up to $100,000,000 (the “Shares”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.